The Group
How the group is built
Alongside its own established business, Tavexia is structured to hold and direct a set of operating companies. Each retains its own name, management and regulatory approvals; the parent provides capital, governance and direction.
The model
Acquire capability, don't claim it.
A pharmaceutical licence is a history as much as a document — of inspections passed, batches released and dossiers accepted. That history stays with the entity that earned it, which is why the group acquires the business rather than the paperwork.
So the group grows by acquiring businesses that already hold what they need, and by leaving those approvals where they sit. The parent's job is to fund the next registration, not to re-badge the last one.
What stays with the operating company
- Its trading name and customer relationships
- Its manufacturing licences and site certifications
- Its product registrations and marketing authorisations
- Its own management team and operational decisions
What moves to the parent
- Capital allocation across the group
- Board oversight and listed-company reporting
- Related-party governance and disclosure
- Group-level market access, where a territory allows the parent to hold the registration
- Intellectual property, technical know-how and technology-transfer arrangements
The corporate mandate
The group's activities sit within the main objects clause of the Memorandum of Association as altered by shareholders in July 2026. That mandate covers the manufacture, formulation, import, export and distribution of bulk drugs, active pharmaceutical ingredients, excipients, pharmaceutical formulations, nutraceuticals and biotechnology products across solid, liquid, injectable and topical delivery systems.
It extends to contract manufacturing and private labelling; to contract research, development and manufacturing services (CRO, CDMO and CRAMS) in India and abroad; and to establishing research and development centres, laboratories, pilot plants and manufacturing facilities. It also provides for intellectual property, joint ventures, technical collaborations and technology-transfer arrangements — the instruments a parent company uses to build a group.
Operating lines
Five businesses, one reporting standard.
Manufacturing and CDMO
Contract development and manufacture across oral solid, oral liquid and external preparations. The group's regulated-manufacturing base and the anchor for its export registrations.
API marketing and distribution
Active pharmaceutical ingredient sourcing and supply. A shorter working-capital cycle than formulations, and a hedge against single-product concentration.
International exports
Finished formulations and APIs into the CIS, Southeast Asia and West Africa, with registrations held at group level wherever the territory permits.
Nutraceuticals and consumer health
Nutraceuticals, biotechnology products and allied lines — a different regulatory route, a different margin profile, and a different demand cycle to prescription products.
Clinical research and BA/BE
The group's next operating line: a bioavailability and bioequivalence centre operating under the CDSCO framework, with contract research, clinical site management, bioanalytical services and regulatory support built around it.
Why clinical research sits inside the group
A generic medicine reaches an export market on the strength of its dossier, and the centre of that dossier is bioequivalence data. Every registration the group files rests on a study someone has to run.
Holding that capability inside the group turns a recurring external cost into an owned asset, and puts the timing of its own filings under its own control. The same facility takes work from external sponsors, so the capacity built for the group's pipeline earns from the wider market between filings.
- Core service
- BA/BE studies
- Framework
- CDSCO / DCGI
- Around it
- CRO · SMO
- Support
- Bioanalytical · IP pharmacy
- Serves
- Group pipeline & external sponsors
Clinical research is planned as an addition to the group. Development is at an early stage and will be disclosed to BSE Limited as it progresses.
Group composition and the status of each line are disclosed in the company's filings with BSE Limited, available under scrip code 539519.
Therapeutic coverage
What the group supplies.
Coverage spanning chronic disease management, acute care and everyday health across nine therapy areas.